Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibiting effect of AKT inhibitor on experimental rat hepatocellular carcinoma

A technology for liver cancer and treatment of liver cancer, applied in the field of medicine, can solve problems such as no related research

Inactive Publication Date: 2019-02-22
SHANDONG UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether TCBN can be used in the experimental or clinical treatment of liver cancer, there is no relevant research at present

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibiting effect of AKT inhibitor on experimental rat hepatocellular carcinoma
  • Inhibiting effect of AKT inhibitor on experimental rat hepatocellular carcinoma
  • Inhibiting effect of AKT inhibitor on experimental rat hepatocellular carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0028] 1. Materials and methods

[0029] Materials: 48 SPF-grade male Wistar rats, weighing 150-160 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (permit number: SYXK (Beijing) 2012-0036). TCBN (HY-15457) was provided by MedChemExpress; DEN (N0756), Anti-AFP primary antibody (SAB3500533) was provided by Sigma-Aldrich; goat anti-rabbit horseradish peroxidase-labeled secondary antibody was purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.; Antibody Diluent (S3022), provided by Dako; SP (Rabbit IgG)-POD Immunohistochemical Kit (SP0021), provided by Beijing Suo Laibao Technology Co., Ltd.; ImmPACT TM DAB peroxidase substrate kit, provided by Vector Laboratories; Alanine transaminase (ALT), aspartate transaminase (Aspartate transaminase, AST), alkaline phosphatase (Alkaline Phosphatase ,ALP), γ-glutamyltransferase (Gamma-glutamyltransferase, γ-GT) kit, provided by Ningbo Meikang Biotechnology Co., Ltd.

[0030] Animal treatm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of triciribine serving as a sole effective component to preparation of a medicine for treating hepatic cancers. Indexes such as weight, hepatic weight and hepaticcoefficient can be remarkably improved by the triciribine serving as the effective component and become more normal, the number of hyperplastic nodules on a hepatic surface is remarkably decreased, the occupied area of the hepatocellular carcinoma is remarkably reduced, and a hepatic lobule structure is improved.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the inhibitory effect of an AKT inhibitor on experimental rat hepatocellular carcinoma. Background technique [0002] The big data study of the global burden of disease on the incidence of liver cancer shows that the incidence of liver cancer increased by 75% from 1990 to 2015, and 810,000 of the 854,000 liver cancer patients worldwide died in 2015. Because liver cancer has rapid development, easy metastasis, poor prognosis, and high recurrence rate, it is of great significance to find suitable intervention agents for early intervention. [0003] Triciribine (TCBN) has been used as a cytotoxic drug in the clinical treatment of breast cancer since the 1980s. In recent years, it has been found that it can selectively inhibit the phosphorylation of AKT to inhibit its activity, so low-dose TCBN was applied to phase I clinical trials of breast cancer solid tumors. However, whether TCBN can b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7064A61P1/16A61P35/00
CPCA61K31/7064A61P1/16A61P35/00
Inventor 张翠丽曾涛赵秀兰于丽华谢克勤
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com